EN DE
STOCK COMPARISON

Sarana Meditama Metropolitan vs HCA Healthcare: Fair Value & Quality

Both stocks run through our valuation models. Here is how Sarana Meditama Metropolitan (SAME) and HCA Healthcare (HCA) compare, as of Aug 10, 2026.

As of Aug 10, 2026, Fair Value Calculator sees HCA Healthcare as the more attractively valued of the two: Sarana Meditama Metropolitan trades at IDR 298 versus a fair value of IDR 42 (-86%), while HCA Healthcare trades at $413 versus $555 (+34%).
Sarana Meditama Metropolitan
SAME.JK · IDR · Health Care
-86%
upside to fair value
overvalued
PriceIDR 298
Fair ValueIDR 42
Quality49/100
HCA Healthcare
HCA · USD · Health Care
+34%
upside to fair value
undervalued
Price$413
Fair Value$555
Quality70/100

Head-to-head numbers

Green value = the better side for that row (for valuation multiples: lower = cheaper).

Sarana Meditama MetropolitanHCA Healthcare
Valuation
267.3×P/E (TTM)12.5×
2.73×P/S (TTM)1.06×
1.36×P/B—
15.9×EV/EBITDA7.8×
—PEG1.18×
—Dividend yield0.8%
—Dividend per share$2.94
Profitability
1%Net margin9%
4%Operating margin15%
1%Return on equity136%
1%Return on assets12%
Growth
9%Revenue growth (YoY)4%
10.1%Avg. growth/yr (3Y)7.9%
29.7%Avg. growth/yr (5Y)8.0%
Balance & size
0.13×Debt / equity—
$518MMarket cap$81B
expensiveGrowth qualityhealthy

HCA Healthcare leads: 3 to 7 metric wins.

Dash = not meaningfully computable, for example with negative equity.

Quality in detail

The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.

Sarana Meditama Metropolitanof which business quality 49 · market factors 37 HCA Healthcareof which business quality 66 · market factors 46
ProfitabilityMargins and returns on capital today
17
76
Quality GrowthAre margins and returns improving?
52
61
CashflowEarnings quality: real cash, not paper profit
47
62
Fin. StrengthBalance sheet, leverage, solvency risk
52
39
InvestmentDisciplined investing over empire-building
60
75
Low VolatilityCalm price path (market factor)
58
59
MomentumPrice trend over the last 3–12 months (market factor)
31
38
52W MomentumDistance to the 52-week high (market factor)
25
44
Net IssuanceBuybacks instead of dilution
81
100

What the models say

The median fair value (base case) per model family, each in the currency of its trading venue. Green = above the current price, red = below.

Sarana Meditama Metropolitan

DCF ModelsIDR 64
Earnings-BasedIDR 35
Dividend DiscountIDR 18
MultiplesIDR 52
Asset-BasedIDR 148
Growth DCFIDR 7
Economic ProfitIDR 93
Growth EarningsIDR 42

23 of 24 models see the stock below the current price.

HCA Healthcare

DCF Models$546
Earnings-Based$289
Dividend Discount$53.85
Multiples$673
Growth DCF$540
Economic Profit$419
Growth Earnings$506

6 of 23 models see the stock below the current price.

Scenario ranges

From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.

Sarana Meditama Metropolitan
Bear IDR 29Fair Value IDR 42Bull IDR 55
IDR 298 = current price (white tick)
HCA Healthcare
Bear $270Fair Value $555Bull $841
$413 = current price (white tick)

Compare two other stocks

Tap a field and type again, ticker or company name.

Free, no sign-up

Ranked within their sector

Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.

Sarana Meditama Metropolitan · Health Care

Quality score49 · below median
Fair value upside-86% · bottom 25%

HCA Healthcare · Health Care

Quality score70 · Top 25%
Fair value upside+34% · Top 25%

Bottom line

As of Aug 10, 2026, Fair Value Calculator sees HCA Healthcare as the more attractively valued of the two: Sarana Meditama Metropolitan trades at IDR 298 versus a fair value of IDR 42 (-86%), while HCA Healthcare trades at $413 versus $555 (+34%).

HCA Healthcare has the higher quality score (70/100).

See the full analysis →
Sarana Meditama Metropolitan · HCA Healthcare

More comparisons

Popular match-ups from the same sectors, all with fair value and quality score.

Related to Sarana Meditama Metropolitan

Eli Lilly and vs UnitedHealth GroupJohnson & Johnson vs UnitedHealth GroupAbbVie vs UnitedHealth GroupUnitedHealth Group vs Merck & Company

Related to HCA Healthcare

UnitedHealth Group vs AstraZenecaUnitedHealth Group vs Thermo Fisher ScientificUnitedHealth Group vs AmgenUnitedHealth Group vs Abbott Laboratories
Free · Top-25 report

See the undervalued quality stocks every month

Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.

A model-based valuation snapshot from 21 models. Values change with price and fundamentals; the date shown above applies.